Each medicine has its own schedule
Tirzepatide acts on GIP and GLP-1 receptors. Semaglutide acts on GLP-1 receptors only. Each product has its own starting dose, escalation steps, formulation and evidence. A bigger milligram number does not make one drug stronger in a way you can convert.
Your experience on another medicine informs the assessment. On its own, this does not justify starting Mounjaro at a high strength. The UK licensed tirzepatide schedule starts at 2.5 mg weekly. Any other starting plan needs a clear clinical reason, and an internet equivalence table is no such reason.
Start with why you want to change
Switching because of too little benefit differs from switching because of vomiting, suspected pancreatitis, supply problems or cost. Some side effects are shared across this group of medicines, so a new brand may not fix the problem. A severe symptom may need investigating before any new medicine starts.
Be clear about the outcome you want: better glucose control, easier treatment, lasting weight management or reliable supply. No product guarantees a better experience for every person, even when average trial results differ.
Give your new clinician the full history
Share the exact medicine and formulation, your last dose, how long you took that dose, any gaps, your weight history and relevant glucose results. Include side effects and why you stopped. A photo of an old box may not show what you took.
Tell the clinician about any unregulated product, compounded preparation or dose change you made yourself. The aim is to understand your exposure and avoid harm. Nobody is judging you. Unknown contents or dosing may mean extra assessment.
Avoid taking both at once
Do not take both medicines while you wait to see which works better. Different brand names can contain the same active ingredient. Overlapping incretin treatments add burden with no proven benefit. Ask for written dates for your last old dose and your first new dose.
The gap between medicines depends on the drugs involved, your symptoms and your clinical situation. No single switching interval applies to everyone. Your pharmacy should reconcile old and new prescriptions so automatic renewals do not create duplicate supplies or confusing reminders.
The first weeks after switching
Arrange a review of side effects, eating and drinking, and effect. If you have diabetes, you may need glucose monitoring and changes to other treatment. If you use oral contraception, follow the specific tirzepatide precautions when you start Mounjaro, even if your previous drug needed none.
Check storage and get device training, because similar-looking products may work differently. If you are switching after a long break, ask directly about the restart dose. A good switch is one you understand, with monitoring and a plan you can keep up. Getting to a higher dose fast, or chasing a better trial headline, is the wrong goal.
Sources
Your own medicine leaflet and prescriber come first. A source from another country does not mean the same rule applies in the UK.
- Mounjaro UK Summary of Product Characteristics, updated September 2026 medicines.org.uk
- Mounjaro UK patient information leaflet medicines.org.uk
- NICE: prescribing, reviewing and stopping tirzepatide nice.org.uk
- NHS Specialist Pharmacy Service: GLP-1 considerations and interactions sps.nhs.uk
- MHRA: GLP-1 medicines, what you need to know gov.uk
Spotted something out of date? Report a mistake.